Share Name Share Symbol Market Type Share ISIN Share Description
Eco Animal Health Group LSE:EAH London Ordinary Share GB0032036807 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +7.50p +1.36% 557.50p 545.00p 570.00p 557.50p 550.00p 550.00p 26,165 10:09:49
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 61.4 13.5 16.4 34.1 366.57

Eco Animal Health Share Discussion Threads

Showing 851 to 874 of 875 messages
Chat Pages: 35  34  33  32  31  30  29  28  27  26  25  24  Older
DateSubjectAuthorDiscuss
17/11/2017
10:22
Couldn't top up online
mad foetus
17/11/2017
09:48
I am tempted, feels like this could be a change...
mad foetus
17/11/2017
08:56
Maybe that's contributed to some recent weakness on a range of AIM shares although I tend to think any effect would be relatively minor and short lived.Price ticked up for the first time in ages. Wonder whether this is the start of a gradual move upwards towards results.
hydrus
16/11/2017
09:27
Any thoughts on the inheritance tax premium on aim shares that might be removed in the budget (an easy win for the chancellor)
rzbrdbe
16/11/2017
09:06
Bvxp on the move. Hopefully EAH will spring to life shortly. RSI is currently 1.31, the lowest I have ever seen for any share!
mad foetus
10/11/2017
09:32
Well I've topped up again - I'm not a chartist but even I can see that this looks like the bottom of a long term upward channel. Will find out in Dec if that was a sensible decision.
hydrus
09/11/2017
16:15
Yes, I suspect so too. MMs will want stock ahead of buying coming in as soon as interims are out in 4-5 weeks from now. However, buyers are now already beginning to appear on the scene so perhaps there'll not be much, or any,further slippage in the share price Even if there is, it's of no real consequence to, I imagine, almost all who are invested here.
aimingupward2
09/11/2017
10:27
I suspect that the MM's are just shaking a few weak holders out ahead of the next results.
winston8643
08/11/2017
16:28
Its taken quite a battering in recent weeks. It has been known to have large falls on minimal volume. So the key question is will the interim results in December continue to show a dramatic upturn in sales and profit? I see no reason why this shouldn't be the case as the have continued to gain new approvals and the GBP/USD rate remains favourable. I am also assuming their continues to be strong demand. I may buy more some time this week....my challenge is deciding which shares to sell to raise the cash!
audigger
08/11/2017
15:16
Minimal volume but what a harsh mark down. Really got my timing wrong here
mad foetus
01/11/2017
13:51
Http://www.ecoanimalhealthgroupplc.com/investor-relations.aspx Date Event 31 March Financial year end April Interim dividend payment July Annual report September Annual general meeting October Interim Dividend December Interim results
grupo guitarlumber
29/10/2017
16:40
Well, well! Another newcomer to welcome to the thread. I don't have any problem with Peter Lawrence taking out some of his reward after many years of building up the business. As has happened in the past, this could very well be, at least partly, the result of one or more institutional buyers persuading him to let them in.
aimingupward2
29/10/2017
16:23
I would also like express thanks for the contributions this weekend. I bought in earlier this year having come to a much more simplistic rationale about moats, more markets and more products. I also liked the fact that Peter Lawrence didn't take any remuneration but recently this was somewhat undermined by him significantly selling down his stake. I think the latter has rattled the share price If I remember correctly I first came across PL 10 years ago when EAH was held in (my) Amati VCT chaired by the same Peter Lawrence. I looked into EAH then. Another one that got away. Good luck to all.
steve3sandal
29/10/2017
12:05
For chemical synthesis, a new plant can cost in the region of 60-100 million. Not sure about the cost of a plant for biological synthesis. This raises the question as to whether they would have to build from scratch or adapt some existing facility. They must have a view as to when demand may exceed supply and hopefully have a plan to deal with this.
audigger
29/10/2017
10:54
O.K.,thanks for the clarification and indeed for joining to this normally very quiet board. You've provided a very welcome contribution.
aimingupward2
29/10/2017
10:47
Yes the upgraded plant
rzbrdbe
29/10/2017
09:57
I’m a bit surprised that you say there’s ‘very little likelihood of another manufacturing facility being built’. So what was “when the new plant is up and running”? Does that refer to the upgraded one in China?
aimingupward2
29/10/2017
09:33
Well I asked Mr Lawrence about this at the AGM that I attended in 2016, he did say that inventory levels would go back to normal when the new plant was up and running. Now he is saying that the increased inventory is to "ensure continuity of supply" I look at this positively in that he might be expecting further increased sales now compared to the position in 2016. I get the impression that there is very little likely hood of another manufacturing facility being built, (as prudent as that might be especially as the one he's got is in China).
rzbrdbe
29/10/2017
09:02
rzbrbde, you raise the matter of increasing inventory stocks of Aivlosin and express some concern about this even though saying that Mr Lawrence has said that this is to ‘ensure continuity of supply’. Given that there is only one production source and that unforeseen events could conceivably put it out of action for a while, I feel that this is a wise precaution, especially given the recent marketing approval in the U.S.A. and expected sales increase, on top of growing sales worldwide. Another possibility, surely, is that the company might seek to establish either an alternative production site or, more likely, a second one. As a prudent safeguard I would hope so. In the circumstances a generous buffer stock is a prudent move, surely?
aimingupward2
28/10/2017
19:07
Thanks for the interesting post RZ, some great insights. The high inventory is only a concern if they don't shift it. Nothing worse than not being able to meet demand! I didn't know they used a biological synthesis as I was led to believe that Aivlosin had a complicated multi-step chemical route of synthesis hence it is very difficult to copy. I had some correspondence with PL and others last year and this reassured me that the IP and patent side of things is secure for years to come. They have other older chemistry which is becoming increasingly profitable but Aivlosin is clearly the major product upon which they are heavily reliant. I see the main risks as being restrictions due to new resistance management strategies imposed by regulators and increased freedom to operate for their competitors. So long as the competition is hurting and they have an effective product to sell in a weak GBP/USD environment, then the bottom line should continue to increase significantly as they reap rewards from the ever growing product range. I've always viewed Elanco as one of the more likely candidates to buy EAH. However I can't see this happening unless they are prepared to pay a significant premium to the current share price December could be very interesting for EAH as we get to learn more about their earnings potential.
audigger
28/10/2017
10:15
rzbrdbe what a helpful and insightful post thank you. My superficial knowledge put to shame.
hydrus
28/10/2017
07:31
I agree that it should be, but if the trend is for using less antibiotics full stop could that impact on Aivlosin? Hopefully the company would educate and overcome any confusion
hydrus
28/10/2017
07:01
My understanding is that this will be beneficial to EAH as Aivlosin has very low to zero residues hence it poses a lesser risk of conferring resistance.
audigger
27/10/2017
20:29
This should in theory be good for EAH as Aivlosin isn't like other antibiotics. However I guess the danger is that a blanket ban comes in to force at some point. Or they just get phased out slowly. https://www.theguardian.com/environment/2017/oct/27/farming-sector-aims-to-cut-antibiotics-use-to-help-tackle-human-resistance
hydrus
Chat Pages: 35  34  33  32  31  30  29  28  27  26  25  24  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20171119 03:25:17